GREENBROOK TMS ANNOUNCES ACCEPTANCE OF ITS MANAGEMENT CEASE TRADE ORDER APPLICATION
Get Alerts GBNH Hot Sheet
Join SI Premium – FREE
Greenbrook made the application in connection with its default with respect to not having filed its annual report on Form 20-F for the year ended
The management cease trade order is to remain in place until two full business days after Greenbrook files the Required Documents and restricts all trading by
Greenbrook applied for a management cease trade order as an alternative to the imposition by the OSC of a general cease trade order. The management cease trade order prevents the persons named in the order from trading in Greenbrook's securities but does not affect the ability of other shareholders, including the public, to trade in securities of Greenbrook.
As previously announced, Greenbrook's filing of the Required Documents has been delayed as both management and the Company's external auditors,
The Company is continuing to work diligently to complete the preparation of the analysis to conclude and facilitate the audit of the annual consolidated financial statements by
Greenbrook confirms that it will satisfy the provisions of the alternative information guidelines under NP 12-203 by issuing bi-weekly default status reports in the form of news releases for so long as it remains in default of the above-noted filing requirements.
Operating through 133 Company-operated treatment centers (following completion of the Restructuring Plan), Greenbrook is a leading provider of Transcranial Magnetic Stimulation ("TMS") and Spravato® (esketamine nasal spray), FDA-cleared, non-invasive therapies for the treatment of Major Depressive Disorder ("MDD") and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Spravato® is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. Greenbrook has provided more than one million treatments to over 27,000 patients struggling with depression.
Certain information in this press release, including statements regarding the timing, review, audit, completion and filing of the Required Documents, constitute forward-looking information within the meaning of applicable securities laws in
Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, risks relating to our ability to successfully complete the Restructuring Plan, risks relating to our ability to satisfy cash requirements necessary to operate our business and remain in compliance with our credit facility, macroeconomic factors such as inflation and recessionary conditions, as well as the factors described in greater detail in the "Risk Factors" section of the Company's annual report on Form 20-F for the fiscal year ended
View original content:https://www.prnewswire.com/news-releases/greenbrook-tms-announces-acceptance-of-its-management-cease-trade-order-application-301791599.html
SOURCE
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tenon Medical gets FDA clearance for updated SI joint fusion system
- Peraso secures $25M equity facility with Roth unit
- Cumberland Farms files for IPO on Nasdaq under ticker CMBY
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share